Glyclopyramide

From Wikipedia, the free encyclopedia

Glyclopyramide

Systematic (IUPAC) name
4-chloro-N-[(pyrrolidin-1-ylamino)carbonyl]benzenesulfonamide
Clinical data
Legal status	℞ Prescription only
Routes	Oral
Identifiers

ATC code	None
PubChem	CID 71793
UNII	KE474IKG1W^Y
KEGG	D01799^Y
Chemical data
Formula	C₁₁H₁₄Cl N₃O₃S
Mol. mass	303.76 g/mol
SMILES C1CCN(C1)NC(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
Y (what is this?) (verify)

Glyclopyramide (INN, marketed under the tradename Deamelin-S) is a sulfonylurea drug used in the treatment of diabetes. It has been marketed in Japan since 1965.

It is classified as second generation.^[1]

References

↑ Ozawa H, Murai Y, Ozawa T (2003). "[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]". Yakugaku Zasshi (in Japanese) 38 (1): 11–27. PMID 14570054.

(Japanese) Deamelin-S 250 mg Tablets

Oral anti-diabetic drugs and Insulin analogs (A10)

Insulin

Sensitizers

Biguanides	Metformin^# Buformin^‡ Phenformin^‡

TZDs/"glitazones" (PPAR)	Pioglitazone Rivoglitazone^† Rosiglitazone Troglitazone^‡

Dual PPAR agonists	Aleglitazar^† Muraglitazar^§ Saroglitazar Tesaglitazar^§

Secretagogues

K+ ATP

Sulfonylureas	1st generation: Acetohexamide Carbutamide Chlorpropamide Metahexamide Tolbutamide Tolazamide 2nd generation: Glibenclamide (Glyburide)^# Glibornuride Glipizide Gliquidone Glisoxepide Glyclopyramide Glimepiride Gliclazide

Meglitinides/"glinides"	Nateglinide Repaglinide Mitiglinide

GLP-1 agonists

DPP-4 inhibitors

GPR40 Free fatty acid receptor 1

Fasiglifam^†

Analogs/other insulins

fast-acting (Insulin lispro
Insulin aspart
Insulin glulisine)
short-acting (Regular insulin)
long-acting (Insulin glargine
Insulin detemir
NPH insulin)
ultra-long-acting (Insulin degludec^†)
inhalable Exubera^‡

Other

Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose

Amylin analog	Pramlintide

SGLT2 inhibitors	Canagliflozin Dapagliflozin Empagliflozin^† Remogliflozin^§ Sergliflozin^§ Tofogliflozin^†

Other	Bromocriptine Benfluorex^‡ Tolrestat^‡

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

M: END

anat/phys/devp/horm

noco (d)/cong/tumr, sysi/epon

proc, drug (A10/H1/H2/H3/H5)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.